The DOI matches its Crossref record.
Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs
Open accessAbstract
BACKGROUND: Ebola virus causes a hemorrhagic fever syndrome that is associated with high mortality in humans. In the absence of effective therapies for Ebola virus infection, the development of a vaccine becomes an important strategy to contain outbreaks. Immunization with DNA and/or replication-defective adenoviral vectors (rAd) encoding the Ebola glycoprotein (GP) and nucleoprotein (NP) has been previously shown to confer specific protective immunity in nonhuman primates. GP can exert cytopathic effects on transfected cells in vitro, and multiple GP forms have been identified in nature, raising the question of which would be optimal for a human vaccine. METHODS AND FINDINGS: To address this question, we have explored the efficacy of mutant GPs from multiple Ebola virus strains with reduced in vitro cytopathicity and analyzed their protective effects in the primate challenge model, with or without NP. Deletion of the GP transmembrane domain eliminated in vitro cytopathicity but reduced its protective efficacy by at least one order of magnitude. In contrast, a point mutation was identified that abolished this cytopathicity but retained immunogenicity and conferred immune protection in the absence of NP. The minimal effective rAd dose was established at 10(10) particles, two logs lower than that used previously. CONCLUSIONS: Expression of specific GPs alone vectored by rAd are sufficient to confer protection against lethal challenge in a relevant nonhuman primate model. Elimination of NP from the vaccine and dose reductions to 10(10) rAd particles do not diminish protection and simplify the vaccine, providing the basis for selection of a human vaccine candidate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor
Lee, J. E., Fusco, M. L., Hessell, A. J., Oswald, W. B., Burton, D. R., & Saphire, E. O. (2008) · Nature · doi:10.1038/nature07082 · Cited by 736
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody
Corti, D., Misasi, J., Mulangu, S., Stanley, D. A., Kanekiyo, M., Wollen, S., Ploquin, A., Doria-Rose, N. A., Staupe, R. P., Bailey, M., et al. (2016) · Science · doi:10.1126/science.aad5224 · Cited by 408
Self-citationA Recombinant Vesicular Stomatitis Virus Ebola Vaccine
Regules, J. A., Beigel, J. H., Paolino, K. M., Voell, J., Castellano, A. R., Hu, Z., Muñoz, P., Moon, J. E., Ruck, R. C., Bennett, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1414216 · Cited by 387
Self-citationStanley, D. A., Honko, A. N., Asiedu, C., Trefry, J. C., Lau-Kilby, A. W., Johnson, J. C., Hensley, L., Ammendola, V., Abbate, A., Grazioli, F., et al. (2014) · Nature Medicine · doi:10.1038/nm.3702 · Cited by 350
Self-citationChimpanzee Adenovirus Vector Ebola Vaccine
Ledgerwood, J. E., DeZure, A. D., Stanley, D. A., Coates, E. E., Novik, L., Enama, M. E., Berkowitz, N. M., Hu, Z., Joshi, G., Ploquin, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1410863 · Cited by 285
Self-citationGeisbert, T. W., Geisbert, J. B., Leung, A., Daddario-DiCaprio, K. M., Hensley, L. E., Grolla, A., & Feldmann, H. (2009) · Journal of Virology · doi:10.1128/jvi.00561-09 · Cited by 275
Self-citationWarfield, K. L., Swenson, D. L., Olinger, G. G., Kalina, W. V., Aman, M. J., & Bavari, S. (2007) · The Journal of Infectious Diseases · doi:10.1086/520583 · Cited by 260
Metadata
- Authors
- Sullivan, N. J., Geisbert, T. W., Geisbert, J. B., Shedlock, D. J., Xu, L., Lamoreaux, L., Custers, J. H. H. V., Popernack, P. M., Yang, Z.-Y., Pau, M. G., Roederer, M., Koup, R. A., Goudsmit, J., Jahrling, P. B., & Nabel, G. J.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2006-05-16
- Volume
- 3
- Issue
- 6
- Pages
- e177
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2075938204
- Cited by
- 205
- References
- 0
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.